- Home
- SKK vs ZBIO Comparison
SKK vs ZBIO Comparison
Compare SKK & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKK
- ZBIO
- Stock Information
- Founded
- SKK 2013
- ZBIO 2019
- Country
- SKK Singapore
- ZBIO United States
- Employees
- SKK N/A
- ZBIO N/A
- Industry
- SKK
- ZBIO
- Sector
- SKK
- ZBIO
- Exchange
- SKK NYSE
- ZBIO NYSE
- Market Cap
- SKK 11.6M
- ZBIO 389.2M
- IPO Year
- SKK 2024
- ZBIO 2024
- Fundamental
- Price
- SKK $0.63
- ZBIO $10.41
- Analyst Decision
- SKK
- ZBIO Strong Buy
- Analyst Count
- SKK 0
- ZBIO 7
- Target Price
- SKK N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- SKK 92.0K
- ZBIO 221.4K
- Earning Date
- SKK 02-14-2025
- ZBIO 08-16-2025
- Dividend Yield
- SKK N/A
- ZBIO N/A
- EPS Growth
- SKK 99.13
- ZBIO N/A
- EPS
- SKK 0.03
- ZBIO N/A
- Revenue
- SKK $11,301,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- SKK N/A
- ZBIO $206.00
- Revenue Next Year
- SKK N/A
- ZBIO $41.92
- P/E Ratio
- SKK $22.52
- ZBIO N/A
- Revenue Growth
- SKK 15.80
- ZBIO N/A
- 52 Week Low
- SKK $0.53
- ZBIO $5.83
- 52 Week High
- SKK $11.45
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- SKK N/A
- ZBIO N/A
- Support Level
- SKK N/A
- ZBIO N/A
- Resistance Level
- SKK N/A
- ZBIO N/A
- Average True Range (ATR)
- SKK 0.00
- ZBIO 0.00
- MACD
- SKK 0.00
- ZBIO 0.00
- Stochastic Oscillator
- SKK 0.00
- ZBIO 0.00
About SKK SKK HOLDINGS LIMITED
SKK Holdings Ltd is a civil engineering service provider that specializes in subsurface utility works in Singapore. It construct and maintain various public works and infrastructure projects that serve the society and the environment. Its projects are the subsurface work related to projects undertaken by the Public Utilities Board (PUB) and Singapore Telecommunications Limited. The nature of these projects is related to repairing of pumping mains, sewer maintenance and pipe cable laying.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.